ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?

Frontiers in Aging Neuroscience

Volumn 9, Issue MAR, 2017, Pages

  Petrov, Dmitry ^a   Mansfield, Colin ^a   Moussy, Alain ^a   Hermine, Olivier ^{a,b,c,d,e,f,g}  

^a AB Science   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c INSERM   (France)

^d IMAGINE INSTITUTE   (France)

^e CNRS   (France)

^f Laboratory of Excellence GR Ex   (France)

^g Equipe Labellisee Par la Ligue Nationale Contre le Cancer   (France)

Author keywords

Amyotrophic lateral sclerosis (ALS); Clinical trial; Edaravone; Masitinib; Motor neuron disease; Riluzole

Indexed keywords

ANTIINFLAMMATORY AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CEFTRIAXONE; CELECOXIB; CILIARY NEUROTROPHIC FACTOR; DEXPRAMIPEXOLE; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR; GLATIRAMER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; LITHIUM; MASITINIB; MEMANTINE; NORPHENAZONE; NP 001; OLESOXIME; OMIGAPIL; OSTEOGENIC PROTEIN 1; PIOGLITAZONE; RILUZOLE; SCATTER FACTOR; SOMATOMEDIN C; TALAMPANEL; TIRASEMTIV; UBIDECARENONE; UNCLASSIFIED DRUG; VALPROIC ACID; VASCULOTROPIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG INDUSTRY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OPEN STUDY; OXIDATIVE STRESS; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION RESEARCH; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; UPREGULATION;

EID: 85017382579     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2017.00068     Document Type: Review

References (102)

1. Abe, K., Itoyama, Y., Sobue, G., Tsuji, S., Aoki, M., Doyu, M., et al. (2014). Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph. Lateral Scler. Frontotemporal Degener. 15, 610-617. doi: 10.3109/21678421.2014.959024
2. Adhihetty, P. J., and Beal, M. F. (2008). Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. Neuromolecular Med. 10, 275-290. doi: 10.1007/s12017-008-8053-y
3. Aggarwal, S. P., Zinman, L., Simpson, E., McKinley, J., Jackson, K. E., Pinto, H., et al. (2010). Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9, 481-488. doi: 10.1016/S1474-4422(10)70068-5
4. ALS CNTF Treatment Study Group (1995). A phase I study of recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. Clin. Neuropharmacol. 18, 515-532
5. ALS CNTF Treatment Study Group (1996). A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 46, 1244-1244. doi: 10.1212/WNL.46.5.1244
6. ARISLA (Fondazione Italiana de Ricerca Per La Sclerosi Laterale) (2014). ALS Clinical Trials List. Available at: http://www.alscience.it/attachement/ALSClinTrialsJune 2014.pdf [accessed May 30, 2016]
7. Beal, M. F. (2002). Coenzyme Q10 as a possible treatment for neurodegenerative diseases. Free Radic. Res. 36, 455-460. doi: 10.1080/10715760290021315
8. Bellingham, M. C. (2011). A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: What have we Learned in the Last Decade? CNS Neurosci. Ther. 17, 4-31. doi: 10.1111/j.1755-5949.2009.00116.x
9. Belzil, V. V., Katzman, R. B., and Petrucelli, L. (2016). ALS and FTD: an epigenetic perspective. Acta Neuropathol. 132, 487-502. doi: 10.1007/s00401-016-1587-4
10. Bensimon, G., Lacomblez, L., Delumeau, J. C., Bejuit, R., Truffinet, P., and Meininger, V. (2002). A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J. Neurol. 249, 609-615. doi: 10.1007/s004150200071
11. Bensimon, G., Lacomblez, L., and Meininger, V. (1994). A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 330, 585-591. doi: 10.1056/NEJM199403033300901
12. Berry, J. D., Shefner, J. M., Conwit, R., Schoenfeld, D., Keroack, M., Felsenstein, D., et al. (2013). Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS ONE 8:e61177. doi: 10.1371/journal.pone.0061177
13. Bessman, S. P. (1987). The creatine phosphate energy shuttle-The molecular asymmetry of a "pool.". Anal. Biochem. 161, 519-523. doi: 10.1016/0003-2697(87)90483-0
14. Blondheim, N. R., Levy, Y. S., Ben-Zur, T., Burshtein, A., Cherlow, T., Kan, I., et al. (2006). Human mesenchymal stem cells express neural genes, suggesting a neural predisposition. Stem Cells Dev. 15, 141-164. doi: 10.1089/scd.2006.15.141
15. Borasio, G. D., Robberecht, W., Leigh, P. N., Emile, J., Guiloff, R. J., Jerusalem, F., et al. (1998). A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 51, 583-586. doi: 10.1212/WNL.51.2.583
16. Bordet, T., Buisson, B., Michaud, M., Drouot, C., Galéa, P., Delaage, P., et al. (2007). Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J. Pharmacol. Exp. Ther. 322, 709-720. doi: 10.1124/jpet.107.123000
17. Bozik, M. E., Mitsumoto, H., Brooks, B. R., Rudnicki, S. A., Moore, D. H., Zhang, B., et al. (2014). A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS. Amyotroph. Lateral Scler. Front. Degener. 15, 406-413. doi: 10.3109/21678421.2014.943672
18. Bozzoni, V. (2016). Amyotrophic lateral sclerosis and environmental factors. Funct. Neurol. 31, 7-19. doi: 10.11138/FNeur/2016.31.1.007
19. Bradley, W. G. (1995). A phase I/II study of recombinant brain-derived neurotrophic in patients with ALS. Ann. Neurol. 38:971
20. Carlile, G., Chalmers-Redman, R., Tatton, N., Pong, A., Borden, K., and Tatton, W. (2000). Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Mol. Pharmacol. 57, 2-12
21. Charcot, J.-M., and Joffroy, A. (1869). Deux cas d'atrophie musculaire progressive: avec let'sions de la substance grise et des faisceaux antérolatéraux de la moelle épiniére. Arch. Physiol. Norm. Pathol. 2, 744-760
22. Clerc, P., Lipnick, S., and Willett, C. (2016). A look into the future of ALS research. Drug Discov. Today 21, 939-949. doi: 10.1016/j.drudis.2016.02.002
23. Cudkowicz, M., Bozik, M. E., Ingersoll, E. W., Miller, R., Mitsumoto, H., Shefner, J., et al. (2011). The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat. Med. 17, 1652-1656. doi: 10.1038/nm.2579
24. Cudkowicz, M. E., Shefner, J. M., Schoenfeld, D. A., Zhang, H., Andreasson, K. I., Rothstein, J. D., et al. (2006). Trial of celecoxib in amyotrophic lateral sclerosis. Ann. Neurol. 60, 22-31. doi: 10.1002/ana.20903
25. Cudkowicz, M. E., van den Berg, L. H., Shefner, J. M., Mitsumoto, H., Mora, J. S., Ludolph, A., et al. (2013). Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 12, 1059-1067. doi: 10.1016/S1474-4422(13)70221-7
26. Cudkowicz, M., Shefner, J., and Consortium, N. (2013). STAGE 3 Clinical Trial of Ceftriaxone in Subjects with ALS (S36.001). Available at: http://www.neurology.org/content/80/7_Supplement/S36.001.abstract [accessed June 6, 2016]
27. de Carvalho, M., Pinto, S., Costa, J., Evangelista, T., Ohana, B., and Pinto, A. (2010). A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 11, 456-460. doi: 10.3109/17482968.2010.498521
28. DeLoach, A., Cozart, M., and Kiaei, M. (2015). A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies. Expert Opin. Drug Discov. 10, 1099-1118. doi: 10.1517/17460441.2015.1067197
29. Duong, F., Fournier, J., Keane, P. E., Guenet, J. L., Soubrie, P., Warter, J. M., et al. (1998). The effect of the nonpeptide neurotrophic compound SR57746A on the progression of the disease state of the pmn mouse. Br. J. Pharmacol. 124, 811-817. doi: 10.1038/sj.bjp.0701885
30. Dupuis, L., Dengler, R., Heneka, M. T., Meyer, T., Zierz, S., Kassubek, J., et al. (2012). A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS ONE 7:e37885. doi: 10.1371/journal.pone.0037885
31. Ferrante, K. L., Shefner, J., Zhang, H., Betensky, R., O'Brien, M., Yu, H., et al. (2005). Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology 65, 1834-1836. doi: 10.1212/01.wnl.0000187070.35365.d7
32. Fornai, F., Longone, P., Cafaro, L., Kastsiuchenka, O., Ferrucci, M., Manca, M. L., et al. (2008). Lithium delays progression of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U.S.A. 105, 2052-2057. doi: 10.1073/pnas.0708022105
33. Gordon, P., Moore, D., Miller, R., Florence, J., Verheijde, J., Doorish, C., et al. (2007). Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 6, 1045-1053. doi: 10.1016/S1474-4422(07)70270-3
34. Gordon, P. H., Doorish, C., Montes, J., Mosley, R. L., Mosely, R. L., Diamond, B., et al. (2006). Randomized controlled phase II trial of glatiramer acetate in ALS. Neurology 66, 1117-1119. doi: 10.1212/01.wnl.0000204235.81272.e2
35. Gordon, P. H., Moore, D. H., Gelinas, D. F., Qualls, C., Meister, M. E., Werner, J., et al. (2004). Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 62, 1845-1847. doi: 10.1212/01.WNL.0000125321.92112.7E
36. Gribkoff, V. K., and Bozik, M. E. (2008). KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis. CNS Neurosci. Ther. 14, 215-226. doi: 10.1111/j.1755-5949.2008.00048.x
37. Groeneveld, G. J., Veldink, J. H., van der Tweel, I., Kalmijn, S., Beijer, C., de Visser, M., et al. (2003). A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann. Neurol. 53, 437-445. doi: 10.1002/ana.10554
38. Gurney, M. E. (1997). The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J. Neurol. Sci. 152(Suppl. 1), S67-S73. doi: 10.1016/S0022-510X(97)00247-5
39. Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., et al. (1994). Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264, 1772-1775. doi: 10.1126/science.8209258
40. Henriques, A., Pitzer, C., and Schneider, A. (2010). Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: Where do we stand? Front. Neurosci. 4:32. doi: 10.3389/fnins.2010.00032
41. Hobson, E. V., and McDermott, C. J. (2016). Supportive and symptomatic management of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 12, 526-538. doi: 10.1038/nrneurol.2016.111
42. Islam, A. M. T., Kwak, J., Jung, Y. J., and Kee, Y. (2014). Animal models of amyotrophic lateral sclerosis. Genes Genomes 36, 399-413. doi: 10.1007/978-1-60761-898-0_27
43. Jackson, C. E., McVey, A. L., Rudnicki, S., Dimachkie, M. M., and Barohn, R. J. (2015). Symptom management and end-of-life care in amyotrophic lateral sclerosis. Neurol. Clin. 33, 889-908. doi: 10.1016/j.ncl.2015.07.010
44. Kasarskis, E. J., Shefner, J. M., and Miller, R. (1999). A controlled trial of recombinant methionyl human BDNF in ALS: the BDNF study group (phase III). Neurology 52, 1427-1433. doi: 10.1212/WNL.52.7.1427
45. Kaufmann, P., Thompson, J. L. P., Levy, G., Buchsbaum, R., Shefner, J., Krivickas, L. S., et al. (2009). Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann. Neurol. 66, 235-244. doi: 10.1002/ana.21743
46. Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., et al. (2011). Amyotrophic lateral sclerosis. Lancet 377, 942-955. doi: 10.1016/S0140-6736(10)61156-7
47. Klivenyi, P., Ferrante, R. J., Matthews, R. T., Bogdanov, M. B., Klein, A. M., Andreassen, O. A., et al. (1999). Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. 5, 347-350. doi: 10.1038/6568
48. Kocic, I., Kowianski, P., Rusiecka, I., Lietzau, G., Mansfield, C., Moussy, A., et al. (2015). Neuroprotective effect of masitinib in rats with postischemic stroke. Naunyn Schmiedebergs Arch. Pharmacol. 388, 79-86. doi: 10.1007/s00210-014-1061-6
49. Lacomblez, L., Bensimon, G., Douillet, P., Doppler, V., Salachas, F., and Meininger, V. (2004). Xaliproden in amyotrophic lateral sclerosis: early clinical trials. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 5, 99-106. doi: 10.1080/14660820410018973
50. Lacomblez, L., Bensimon, G., Leigh, P. N., Guillet, P., and Meininger, V. (1996). Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347, 1425-1431. doi: 10.1016/S0140-6736(96)91680-3
51. Lai, E. C., Felice, K. J., Festoff, B. W., Gawel, M. J., Gelinas, D. F., Kratz, R., et al. (1997). Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 49, 1621-1630. doi: 10.1212/WNL.49.6.1621
52. Lauria, G., Campanella, A., Filippini, G., Martini, A., Penza, P., Maggi, L., et al. (2009). Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability. Amyotroph. Lateral Scler. 10, 410-415. doi: 10.3109/17482960902995246
53. Lauria, G., Dalla Bella, E., Antonini, G., Borghero, G., Capasso, M., Caponnetto, C., et al. (2015). Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study. J. Neurol. Neurosurg. Psychiatry 86, 879-886. doi: 10.1136/jnnp-2014-308996
54. Lenglet, T., Lacomblez, L., Abitbol, J. L., Ludolph, A., Mora, J. S., Robberecht, W., et al. (2014). A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur. J. Neurol. 21, 529-536. doi: 10.1111/ene.12344
55. Li, J., Wuliji, O., Li, W., Jiang, Z.-G., and Ghanbari, H. A. (2013). Oxidative stress and neurodegenerative disorders. Int. J. Mol. Sci. 14, 24438-24475. doi: 10.3390/ijms141224438
56. Marin, B., Boumédiene, F., Logroscino, G., Couratier, P., Babron, M.-C., Leutenegger, A. L., et al. (2016). Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int. J. Epidemiol. doi: 10.1093/ije/dyw061 [Epub ahead of print]
57. Meininger, V., Bensimon, G., Bradley, W. R., Brooks, B., Douillet, P., Eisen, A. A., et al. (2004). Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 5, 107-117. doi: 10.1080/14660820410019602
58. Meininger, V., Drory, V. E., Leigh, P. N., Ludolph, A., Robberecht, W., and Silani, V. (2009). Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double-blind, randomized, multicentre, placebo-controlled trial. Amyotroph. Lateral Scler. 10, 378-383. doi: 10.3109/17482960902803432
59. Miller, R., Bradley, W., Cudkowicz, M., Hubble, J., Meininger, V., Mitsumoto, H., et al. (2007a). Phase II/III randomized trial of TCH346 in patients with ALS. Neurology 69, 776-784. doi: 10.1212/01.wnl.0000269676.07319.09
60. Miller, R., Bryan, W., and Munsat, T. (1993). Safety, tolerability and pharmacokinetics of recombinant human ciliary neurotrophic factor (rhCNTF) in patients with amyotrophic lateral sclerosis (ALS). Ann. Neurol. 34:241
61. Miller, R., Mitchell, J. D., Lyon, M., and Dh, M. (2007b). Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. 822, 2007-2009. doi: 10.1002/14651858.CD001447
62. Miller, R. G., Block, G., Katz, J. S., Barohn, R. J., Gopalakrishnan, V., Cudkowicz, M., et al. (2015). Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS. Neurol. Neuroimmunol. Neuroinflammation 2:e100. doi: 10.1212/NXI.0000000000000100
63. Miller, R. G., Petajan, J. H., Bryan, W. W., Armon, C., Barohn, R. J., Goodpasture, J. C., et al. (1996). A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Ann. Neurol. 39, 256-260. doi: 10.1002/ana.410390215
64. Miller, R. G., Zhang, R., Block, G., Katz, J., Barohn, R., Kasarskis, E., et al. (2014). NP001 regulation of macrophage activation markers in ALS: A phase I clinical and biomarker study. Amyotroph. Lateral Scler. Front. Degener. 15, 601-609. doi: 10.3109/21678421.2014.951940
65. Mitsumoto, H., Brooks, B. R., and Silani, V. (2014). Clinical trials in amyotrophic lateral sclerosis: Why so many negative trials and how can trials be improved? Lancet Neurol. 13, 1127-1138. doi: 10.1016/S1474-4422(14)70129-2
66. Morrison, K. E., Dhariwal, S., Hornabrook, R., Savage, L., Burn, D. J., Khoo, T. K., et al. (2013). Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 12, 339-345. doi: 10.1016/S1474-4422(13)70037-1
67. Niedzielska, E., Smaga, I., Gawlik, M., Moniczewski, A., Stankowicz, P., Pera, J., et al. (2015). Oxidative stress in neurodegenerative diseases. Mol. Neurobiol. 53, 1-32. doi: 10.1007/s12035-015-9337-5
68. Palumbo, J., Sakata, T., Tanaka, M., and Akimoto, M. (2016). "Sustained efficacy for up to 12 months in an active extension of a phase III study of edaravone (MCI-186) for treatment of amyotrophic lateral sclerosis (ALS) (P3.190)," in Poster Presented at: AAN 2016 Annual Meeting, Vancouve, BC
69. Pascuzzi, R. M., Shefner, J., Chappell, A. S., Bjerke, J. S., Tamura, R., Chaudhry, V., et al. (2010). A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 11, 266-271. doi: 10.3109/17482960903307805
70. Pastula, D. M., Moore, D. H., and Bedlack, R. S. (2012). Creatine for amyotrophic lateral sclerosis/motor neuron disease. Cochrane database Syst. Rev. 12:CD005225. doi: 10.1002/14651858.CD005225.pub3
71. Perrin, S. (2014). Preclinical research: make mouse studies work. Nature 507, 423-425. doi: 10.1038/507423a
72. Piepers, S., Veldink, J. H., De Jong, S. W., Van Der Tweel, I., Van Der Pol, W. L., Uijtendaal, E. V., et al. (2009). Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann. Neurol. 66, 227-234. doi: 10.1002/ana.21620
73. Piette, F., Belmin, J., Vincent, H., Schmidt, N., Pariel, S., Verny, M., et al. (2011). Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. Alzheimers Res. Ther. 3:16. doi: 10.1186/alzrt75
74. Pontieri, F. E., Ricci, A., Pellicano, C., Benincasa, D., and Buttarelli, F. R. (2005). Minocycline in amyotrophic lateral sclerosis: a pilot study. Neurol. Sci. 26, 285-287. doi: 10.1007/s10072-005-0474-x
75. Riva, N., Agosta, F., Lunetta, C., Filippi, M., and Quattrini, A. (2016). Recent advances in amyotrophic lateral sclerosis. J. Neurol. 263, 1-14. doi: 10.1007/s00415-016-8091-6
76. Rosenfeld, J. (2001). "Creatine monohydrate in amyotrophic lateral sclerosis: preliminary results," in Proceedings of the American Academy of Neurology Annual Meeting, Philadelphia, PA
77. Rosenfeld, J., King, R. M., Jackson, C. E., Bedlack, R. S., Barohn, R. J., Dick, A., et al. (2008). Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS. Amyotroph. Lateral Scler. 9, 266-272. doi: 10.1080/17482960802028890
78. Rothstein, J. D. (1995). Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Adv. Neurol. 68, 7-20; discussion 21-7
79. Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., et al. (2005). Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433, 73-77. doi: 10.1038/nature03180
80. Saccon, R. A., Bunton-Stasyshyn, R. K. A., Fisher, E. M. C., and Fratta, P. (2013). Is SOD1 loss of function involved in amyotrophic lateral sclerosis? Brain 136, 2342-2358. doi: 10.1093/brain/awt097
81. Sagot, Y., Toni, N., Perrelet, D., Lurot, S., King, B., Rixner, H., et al. (2000). An orally active anti-apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motoneuron disease. Br. J. Pharmacol. 131, 721-728. doi: 10.1038/sj.bjp.0703633
82. Sakata, T., Palumbo, J., Akimoto, M., and Tanaka, M. (2016). A long-term safety and efficacy extension study of patients diagnosed with amyotrophic lateral sclerosis (ALS) and treated with edaravone (MCI-186) (P3.192). Neurology 86(Suppl. P3.192)
83. Shefner, J., Cedarbaum, J. M., Cudkowicz, M. E., Maragakis, N., Lee, J., Jones, D., et al. (2012). Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 13, 430-438. doi: 10.3109/17482968.2012.684214
84. Shefner, J. M., Cudkowicz, M. E., Schoenfeld, D., Conrad, T., Taft, J., Chilton, M., et al. (2004). A clinical trial of creatine in ALS. Neurology 63, 1656-1661. doi: 10.1212/01.WNL.0000142992.81995.F0
85. Shefner, J. M., Watson, M. L., Meng, L., and Wolff, A. A. (2013a). A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 14, 574-581. doi: 10.3109/21678421.2013.822517
86. Shefner, J. M., Wolff, A. A., and Meng, L. (2013b). The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS. Amyotroph. Lateral Scler. Front. Degener 14, 582-585. doi: 10.3109/21678421.2013.817587
87. Shefner, J. M., Wolff, A. A., Meng, L., Bian, A., Lee, J., Barragan, D., et al. (2016). A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 17, 426-435. doi: 10.3109/21678421.2016.1148169
88. Sorenson, E. J., Windbank, A. J., Mandrekar, J. N., Bamlet, W. R., Appel, S. H., Armon, C., et al. (2008). Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 71, 1770-1775. doi: 10.1212/01.wnl.0000335970.78664.36
89. Tanaka, M., Sakata, T., Palumbo, J., and Akimoto, M. (2016a). A 24-week, phase III, double-blind, parallel-group study of edaravone (MCI-186) for treatment of amyotrophic lateral sclerosis (ALS) (P3.189). Neurology 86(Suppl. P3.189)
90. Tanaka, M., Sakata, T., Palumbo, J., and Akimoto, M. (2016b). A double-blind, parallel-group, placebo-controlled, 24-week, exploratory study of edaravone (MCI-186) for the treatment of advanced amyotrophic lateral sclerosis (ALS) (P3.191). Neurology 86(Suppl. P3.191)
91. Teva (2010). News Release. Available at: http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=1555496
92. Therrien, M., Dion, P. A., and Rouleau, G. A. (2016). ALS: recent developments from genetics studies. Curr. Neurol. Neurosci. Rep. 16:59. doi: 10.1007/s11910-016-0658-1
93. Thomsen, G. M., Gowing, G., Svendsen, S., and Svendsen, C. N. (2014). The past, present and future of stem cell clinical trials for ALS. Exp. Neurol. 262, 127-137. doi: 10.1016/j.expneurol.2014.02.021
94. Tohgi, H., Abe, T., Yamazaki, K., Murata, T., Ishizaki, E., and Isobe, C. (1999). Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis. Ann. Neurol. 46, 129-131. doi: 10.1002/1531-8249(199907)46:1<129::AID-ANA21>3.0.CO;2-Y
95. Trias, E., Ibarburu, S., Barreto-Núñez, R., Babdor, J., Maciel, T. T., Guillo, M., et al. (2016). Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. J. Neuroinflammation 13:177. doi: 10.1186/s12974-016-0620-9
96. Vermersch, P., Benrabah, R., Schmidt, N., Zéphir, H., Clavelou, P., Vongsouthi, C., et al. (2012). Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurol. 12:36. doi: 10.1186/1471-2377-12-36
97. Verstraete, E., Veldink, J. H., Huisman, M. H. B., Draak, T., Uijtendaal, E. V., van der Kooi, A. J., et al. (2012). Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial. J. Neurol. Neurosurg. Psychiatry 83, 557-564. doi: 10.1136/jnnp-2011-302021
98. Wang, R., and Zhang, D. (2005). Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. Eur. J. Neurosci. 22, 2376-2380. doi: 10.1111/j.1460-9568.2005.04431.x
99. Watanabe, T., Yuki, S., Egawa, M., and Nishi, H. (1994). Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J. Pharmacol. Exp. Ther. 268, 1597-1604
100. Yoshino, H., and Kimura, A. (2006). Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph. Lateral Scler. 7, 241-245. doi: 10.1080/17482960600881870
101. Zhao, W., Beers, D. R., and Appel, S. H. (2013). Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J. Neuroimmune Pharmacol. 8, 888-899. doi: 10.1007/s11481-013-9489-x
102. Zufiría, M., Gil-Bea, F. J., Fernández-Torrón, R., Poza, J. J., Muñoz-Blanco, J. L., Rojas-García, R., et al. (2016). ALS: a bucket of genes, environment, metabolism and unknown ingredients. Prog. Neurobiol. 142, 104-129. doi: 10.1016/j.pneurobio.2016.05.004